Pediatric Academic Societies'
Annual Meeting

 Sponsored by the:

 Program   |   Abstracts    |   Exhibits   |   Registration, Housing, Travel  |   International Attendees   |   Presenters   |   CME   |   Press/Media  |   HOME

 

 

Contact Information

Mail Address:

3400 Research Forest Dr., Ste B-7
The Woodlands, TX  77381 USA

Email:  info@pas-meeting.org

Telephone:  281-419-0052

Facsimile:  281-419-0082

 

2006 PAS Annual Meeting

April 29–May 2 
San Francisco, California

Track/Area of Interest


At A Glance Page 
(PDF format)

Return to 
Schedule Home Page

(as of April 13, 2006) 

Endocrinology and Diabetes

Saturday, April 29

6:00am–8:00am
Diagnosis, Treatment and Cost Analysis of Growth Hormone Deficiency
Industry Sponsored Symposium
Yerba Buena Gardens Salon 8, SF Marriott

Target Audience: Endocrinologists.

The guidelines from the American Association of Clinical Endocrinologists advocate early initiation of growth-hormone replacement therapy in appropriate patients. Accurate diagnosis of growth-hormone deficiency is complicated by other potential causes of idiopathic short stature, including growth-hormone resistance, hypothyroidism, chronic systemic disease, Turner syndrome, or skeletal disorder, which must be eliminated before growth-hormone replacement therapy commences. Topics to be covered in this symposium include differential diagnosis in patients with growth-hormone deficiency, recognizing and overcoming difficulties in achieving an accurate diagnosis, differentiation between IGF resistance and IGF deficiency, and practical and clinical guidelines in developing and maintaining an appropriate therapeutic growth-hormone management strategy.

For registration information please contact:
Shannon Monteith
Phone: (800) 960-0256
Email: smonteith@vindicomeded.com

Supported by a grant from Gate Pharmaceuticals (a Division of Teva)

8:00am–11:00am
2100—Adult Stem Cells—A Primer for the Clinician
PAS/ASPHO Mini Course
Room 3014, Moscone West
Chairs: Jakub Tolar, University of Minnesota, Minneapolis, MN; and Mervin C. Yoder, Jr., Indiana University School of Medicine, Indianapolis, IN

Target Audience: Hematologists/oncologists, endocrinologists, basic scientists and neurologists.

Adult stem cells represent a technology that is being intensively investigated currently, and this research may have wide implications for human health. This mini course will focus on recent research and potential applications in human health.

  • Introduction
    Jakub Tolar, University of Minnesota, Minneapolis, MN
    Mervin C. Yoder, Indiana University School of Medicine, Indianapolis, IN

  • Multipotent Adult Progenitor Cell: Hype or Reality?
    Catherine M. Verfaillie, University of Minnesota, Minneapolis, MN

  • Mesenchymal Stem Cell: Harnessing the Power of Adult Stem Cells To Repair Tissues
    Darwin Prockop, Tulane University Health Science Center, New Orleans, LA

  • Hierarchy of Endothelial Progenitors in Human Blood and Blood Vessels
    David A. Ingram, Indiana University School of Medicine, Indianapolis, IN

  • Cancer Stem Cell: Concept of Human Leukemic Development
    Craig T. Jordan, James P. Wilmot Cancer Center, University of Rochester School of Medicine, Rochester, NY

Sponsored jointly by the American Society of Pediatric Hematology/Oncology and the Pediatric Academic Societies

8:00am–11:00am
2125—New Considerations for the Growth Rate of the Preterm Infant: Too Fast or Not Fast Enough?—A Review of the Evidence
PAS Mini Course
Room 3002-3008, Moscone West
Chairs: Frank R. Greer, University of Wisconsin, Madison, WI; and William W. Hay, Jr., University of Colorado, Aurora, CO

Target Audience: Neonatologists, hospitalists who take care of preterm infants, nutritionists and general pediatricians.

Recent nutritional emphasis in the NICU has been to achieve the normal intrauterine growth rate with more aggressive nutritional support for the low birth weight infant. In general, this has been difficult to achieve, and new evidence from long-term follow up studies shows that preterm infants are at an increased risk of developing the metabolic syndrome including obesity, type 2 diabetes and cardiovascular disease. This implies that the organs in the early life of the preterm infant may be programmed adversely by nutritional therapy. This raises the questions of how fast these infants should grow (including catch up growth), the importance of the composition of this growth and the urgency for defining the necessary balance between growth of the brain and the rest of the body. Ultimately, providers may want to revise the long-term and short-term goals for feeding very low birth weight or extremely low birth weight infants. This mini course will present evidence to help answer these questions and provide discussion about related practice recommendations.

  • Overview
    Frank R. Greer, University of Wisconsin, Madison, WI
    William W. Hay, University of Colorado Health Sciences Center, Aurora, CO

  • Macronutrient Requirements for Growth of Preterm Infants—Upper and Lower Limits (Energy, Fat, CHO, Protein)
    Scott C. Denne, Indiana University School of Medicine, James Whitcomb Riley Hospital, Indianapolis, IN

  • Aggressive Nutritional Support of the Preterm Infant Revisited—Evidence for Efficacy and Safety
    Patti J. Thureen, University of Colorado Health Sciences Center, Denver, CO

  • Adverse Outcomes of Rapid Somatic Growth and Alterations of Body Composition in the Low Birth Weight Infant
    Frank R. Greer, University of Wisconsin, Madison, WI

  • Fatty Acids and Neuronal Development
    Susan E. Carlson, University of Kansas Medical Center, Kansas City, KS

  • Iron and Development of the Brain
    Michael K. Georgieff, University of Minnesota School of Medicine, Minneapolis, MN

  • Nutritional Influences on Structural and Functional Maturation of the Developing Brain During Extended Postnatal Period
    Steve H. Zeisel, The University of North Carolina, Chapel Hill, NC

8:00am–11:00am
2155—Gender-Variant Youth: The Role of the Pediatrician
PAS Educational Workshop
Laurel, SF Marriott
Leader: Irene Sills, Albany, NY; Co-leader: Arlene Lev

Target Audience: Trainees, fellows, junior faculty, mid-level faculty, senior faculty, and community practitioners.

This workshop is an overview of sexual and gender identity development in children and youth focusing on understanding the needs of transgender and transsexual youth. By review of case presentations, attendees will gain skills and knowledge in how to assist parents of children with gender variant behavior, children with gender identity confusion, and adolescents who exhibit cross-gender behaviors. Ethical considerations in the care of this population will be presented and discussed. Current standards for hormonal therapy will be reviewed.

Objectives:

– The participant will demonstrate an understanding of the developmental appropriateness of youth with gender variant behavior.
– The participant will prepare to assist children and adolescents with gender variant behavior and their families.
– The participant will demonstrate an understanding of the ethical issues in the medical care of transgendered adolescents.

Format: a) Short didactic presentation; b) discussions of scenarios that might present to the pediatrician; c) viewing of a short videotape; and d) roundtable discussion of ethical issues.

8:00am–12:00pm
2180A—LWPES Plenary Session I
LWPES Plenary Session
Room 3007-3009, Moscone West
Chairs: Lynne Levitsky, Massachusetts General Hospital, Boston, MA; Henry Anhalt, Saint Barnabas Medical Center, Livingston, NJ; and Alan D. Rogol, University of Virginia, Charlottesville, VA

Target Audience: Endocrinologists, nephrologists, cardiologists, general pediatricians, immunologists, geneticists and molecular biologists.

  • Opening Remarks
    Lynne L. Levitsky, Massachusetts General Hospital, Boston, MA

  • Lawson Wilkins Lecture:
    Recent years have witnessed a significant revision of the traditional view of fat cells as simple stores of excess energy. Studies in the speaker's lab as well as many others have clearly demonstrated that adipocytes produce and regulate many metabolic and hormonal signals, which generate profound effects on systemic endocrine equilibrium. In his earlier studies, he also demonstrated that these cells exhibit an inflammatory capacity that is abnormal in obesity and key to the pathogenesis of insulin resistance and diabetes. Recently, he identified a key molecular mechanism underlying the link between inflammatory responses and insulin action. This pathway involves obesity-related activation of the serine, threonine kinase, JNK, and the consequent inhibition of insulin receptor signaling via phosphorylation of a substrate of insulin receptor, IRS-1.

    • Integration of Metabolic and Inflammatory Pathways in Metabolic Disease
      Gokhan S. Hotamisligil, Harvard School of Public Health, Boston, MA

  • Robert Blizzard Lecture:
    One of the greatest questions asked of physicians caring for children with autoimmune diabetes is "why did this happen?" This session will unravel some of the mysteries surrounding the etiology and pathogenesis of autoimmune diabetes from an investigator who has dedicated his life to this issue.

    • On the Unravelling of the Etiopathogenesis of Type 1 Diabetes: Are We Stuck or Are We Winning?
      Gian Franco Bottazzo, Ospedale Pediatrico Bambino Gesú, Scientific Institute, Rome, Italy

  • Break

  • Esoterix Lecture:
    The attendee will familiarize him/herself with newer molecular mechanisms of growth failure that are due to abnormalities in receptor and post-receptor translation of GH signaling.

    • Molecular Mechanisms and Defects in Growth Hormone Receptor Signaling
      Peter Rotwein, Oregon Health and Science University, Portland, OR

11:45am–2:45pm
2424—Treatment of the Metabolic Syndrome in Children and Adolescents
PAS Educational Workshop
Golden Gate Hall A1, SF Marriott
Leader: J. Darrell Nesmith, Little Rock, AR; Co-leaders: Alba Morales, Mohammad Ilyas, Lisa Lubsch

Target Audience: Endocrinologists, trainees, fellows, junior faculty, mid-level faculty, senior faculty, and community practitioners.

The rise in pediatric obesity and metabolic syndrome is well established. Less understood for the pediatrician is the treatment of the metabolic syndrome. In this workshop, we aim to: 1) briefly discuss the epidemiology of the metabolic syndrome in children and adolescents, 2) discuss non-pharmacologic and pharmacologic treatment of the metabolic syndrome, and 3) review a stepped approach in treating adolescents with the metabolic syndrome.

This workshop will be largely case-based. Come prepared to devise treatment plans in a small group setting. Participants are invited to bring their own cases for discussion.

Objectives:

Participants will:

– Learn the epidemiology of the metabolic syndrome in children and adolescents.
– Become familiar with existing treatment guidelines for components of the metabolic syndrome in children and adolescents.
– Identify gaps in the literature regarding treatment guidelines of the metabolic syndrome in children and adolescents.
– Consider pharmacologic treatment options of metabolic syndrome treatment based on the available evidence.

Format: A short didactic presentation will be given on diabetes, hypertension, and dyslipidemia treatments from a diabetologist, nephrologist, and endocrinologist respectively. Existing published guidelines will be presented while gaps in the literature regarding treatment will be discussed. Following these short didactic presentations, small groups (at tables) will work on cases which will be presented, and a treatment plan will be derived by each group. At the end of these roundtable work group discussions, the group as a whole will discuss the treatment plans. Actual cases will be used when possible (with appropriate de-identifiers) and their treatment plans discussed.

12:00pm–3:00pm
2505—Embryonic Stem Cells: A Primer for Clinicians
PAS Mini Course
Room 3014, Moscone West
Chair: Michael T. Longaker, Stanford University, Stanford, CA

Embryonic stem cells offer incredible promise for treating diseases affecting both children and adults. This mini course will provide an overview of stem cells and a basic understanding of how to derive human embryonic stem cells, recent research and ethical considerations. After attending this session, attendee will have a better understanding of: 1) what are embryonic stem cells; 2) how human embryonic stem cells are derived; 3) recent progress in human embryonic stem cell research; 4) ethical considerations in human embryonic stem cells.

  • Stem Cells: Embryonic, Adult and Cancer
    Michael T. Longaker, Stanford University, Stanford, CA

  • What It Takes Clinically To Get an Embryonic Stem Cell
    Linda C. Giudice, University of California, San Francisco, San Francisco, CA

  • What Can You Do with an Embryonic Stem Cell in Research
    Renee Reijo Pera, University of California, San Francisco, San Francisco, CA

  • Ethical and Oversight Considerations in Human Embryonic Stem Cell Research
    Hank Greely, Stanford University, Stanford, CA

  • Panel Discussion

Supported in part by an unrestricted educational grant from Treuman Katz Center for Pediatric Bioethics - Seattle Children's Hospital

1:30pm–3:30pm
2670A—Controversies in Care in Pediatric Endocrinology—The Great Debates
LWPES Workshop
Room 3001, Moscone West
Chairs: William Clarke, University of Virginia, Charlottesville, VA; and Henry Anhalt, St. Barnabas Medical Center, Livingston, NJ

Target Audience: Endocrinologists, general pediatricians and adolescent medicine specialists.

The attendee will be part of a lively debate on a number of areas of controversy in pediatric state-of-the-art diabetes management.

  • Is Primary Prevention of Type 1 Diabetes Possible?

    • Pro—Desmond A. Schatz, University of Florida, Gainesville, FL

    • Con—Dorothy J. Becker, Children's Hospital of Pittsburgh, Pittsburgh, PA

  • Should Glucose Sensors Be Routinely Used?

    • Pro—Stuart Alan Weinzimer, Yale School of Medicine, New Haven, CT

    • Con—Darrell M. Wilson, Stanford University Medical Center, Stanford, CA

  • Should Metformin Be Used To Treat Pediatric Patients with Insulin Resistance?

    • Pro—Michael S. Freemark, Duke University Medical Center, Durham, NC

    • Con—Philip Scott Zeitler, University of Colorado at Denver and Health Sciences Center, Denver, CO

1:30pm–3:30pm
2675A—Controversies in the Management of Non-classical Congenital Adrenal Hyperplasia
LWPES Workshop
Room 3000, Moscone West
Chairs: Perrin White, University of Texas Southwestern Medical Center, Dallas, TX; and Ieuan Hughes, University of Cambridge, Cambridge, UK

Target Audience: Neonatologists, endocrinologists, generalists and adolescent medicine specialists.

Non-classical adrenal hyperplasia (NCAH) occurs more commonly than does the classical form and may masquerade as hirsutism, acne and menstrual cycle dysfunction. NCAH must be considered in the differential diagnosis of these relatively common conditions. The diagnosis of NCAH is being made more frequently today as a result of greater access to genotyping available through many commercial laboratories. Once the diagnosis is made, however, the controversies begin. Who should have stress-dose glucocorticoids and who should have prenatal screening are some of the controversial issues.

  • Glucocorticoid Coverage and Treatment in Non-classical Adrenal Hyperplasia
    Mitchell E. Geffner, Children's Hospital Los Angeles, Los Angeles, CA

  • Role or No Role of Prenatal Diagnosis and Newborn Screening in Non-classical Adrenal Hyperplasia
    Patricia A. Donohoue, The Children's Hospital of Iowa at the University of Iowa Hospitals and Clinics, Iowa City, IA

  • Fertility in Patients with Non-classical Adrenal Hyperplasia
    Marcelle Cedars, University of California-San Francisco, San Francisco, CA

2:15pm–5:15pm
2700—Educating Pediatric Fellows in a Competency-Based World
PAS/APPD Mini Course
Room 2007, Moscone West
Chairs: Susan Guralnick, Stony Brook University Medical Center, Stony Brook, NY; and Joseph Gilhooly, Oregon Health and Science University, Portland, OR

Target Audience: Attendees involved with fellowship programs.

Competency-based education is now the standard for residency education. Residency programs have integrated the ACGME Core Competencies into their curricula and assessment methods. It is now time for fellowships to enter the “competency” arena, and there is much to be accomplished. This program will focus on several areas of fellowship education including: the new RRC common requirements for subspecialty training, development of a competency-based fellowship curriculum, competency-based assessment tools, and pediatric subspecialty fellows as teachers. Attendees are encouraged to bring tools and ideas for discussion and development. Attendees should leave with useful materials to bring back to their home programs.

  • Overview
    Susan Guralnick, Stony Brook University Medical Center, Stony Brook, NY
    Joseph Gilhooly, Oregon Health & Science University, Portland, OR

  • A Brave New World! New Common Requirements for Subspecialty Training—Implementing the Competencies
    Carol Carraccio, Professor of Pediatrics and Associate Chair for Education, University of Maryland School of Medicine, Baltimore, MD

  • "Survivor ACGME"—Fellowship Competencies in Action
    Joseph Gilhooly, Oregon Health & Science University, Portland, OR

  • John D. Mahan, Children’s Hospital, The Ohio State University, Columbus, OH

  • Turning to Fellows as Teachers: From Curricula to Evaluation
    Nancy D. Spector, St. Christopher's Hospital for Children, Philadelphia, PA
    Susan Guralnick, Stony Brook University Medical Center, Stony Brook, NY

Sponsored jointly by the Association of Pediatric Program Directors and the Pediatric Academic Societies

Supported by an unrestricted educational grant from Dey, L.P.

2:15pm–5:15pm
2705—Vitamin D: More Than Just Calcium and Bone
PAS/LWPES Mini Course
Room 3007-3009, Moscone West
Chairs: Catherine M. Gordon, Children's Hospital of Boston, Boston, MA; and Linda A. DiMeglio, Indiana University, Indianapolis, IN

Target Audience: General pediatricians, gastroenterologists, endocrinologists and hematologists/oncologists.

The understanding of the role of vitamin D in health and illness is becoming more complex. Both skeletal and extra-skeletal actions have been described, and vitamin D analogs are being explored for their anti-proliferative effects. The attendee will gain both clinically relevant epidemiological knowledge as well as review the calcemic and non-calcemic actions of Vitamin D.

  • What Is the Evidence for Vitamin D Deficiency in Children?
    Frank R. Greer, University of Wisconsin, Madison, WI

  • Vitamin D and Extra-Skeletal Actions in Health
    Michael F. Holick, Boston University School of Medicine, Boston, MA

  • Non-calcemic Actions of Vitamin D Receptor Ligands
    Sunil Nagpal, Women's Health & Musculoskeletal Biology, Collegeville PA

Sponsored jointly by the Lawson Wilkins Pediatric Endocrine Society and the Pediatric Academic Societies

3:15pm–5:15pm
2730—Mechanisms of Hypertension in the Molecular Era
PAS/ASPN/IPHA/LWPES Topic Symposium
Room 2003-2005, Moscone West
Chairs: Bruce Z. Morgenstern, Phoenix Children's Hospital, Phoenix, AZ; and Julie R. Ingelfinger, Massachusetts General Hospital, Boston, MA

Target Audience: General pediatricians, nephrologists, endocrinologists and neonatologists.

Our understanding of the pathophysiology of hypertension has been changing rapidly due to advances in molecular genetics, most notably the identification of several single-gene defects that cause hypertension. This session will update participants on the latest advances in our knowledge of molecular mechanisms of a variety of forms of hypertension.

  • Role of Dopamine Receptors
    Pedro A. Jose, Georgetown University Medical Center, Washington, DC

  • Perinatal Programming and the Development of Hypertension
    Lori Woods, Oregon Health & Science University, Portland, OR

  • Low Renin Hypertension in Childhood
    Maria I. New, Mount Sinai School of Medicine, New York, NY

  • WNK Kinases and Blood Pressure Regulation
    Richard Lifton, Yale University School of Medicine, New Haven, CT

Sponsored jointly by the American Society of Pediatric Nephrology, the International Pediatric Hypertension Association, the Lawson Wilkins Pediatric Endocrine Society and the Pediatric Academic Societies

3:45pm–5:15pm
2785A—Celiac Disease for the Non-gastroenterologist
LWPES Workshop
Room 3010, Moscone West
Chair: Michelle M. Pietzak, Children's Hospital of Los Angeles, Los Angeles, CA

Target Audience: Gastroenterologists and endocrinologists.

Celiac disease affects approximately 10-15% of children with diabetes. Often times the screening tests are vexing. This workshop is aimed at clarifying the disease process and how to diagnose it.

  • Celiac Disease for the Non-gastroenterologist
    Michelle M. Pietzak, Children's Hospital of Los Angeles, Los Angeles, CA

3:45pm–5:15pm
2790A—Hyperthyroidism
LWPES Workshop
Room 3000, Moscone West
Chair: Scott A. Rivkees, Yale School of Medicine, New Haven, CT

Target Audience: Generalists.

Much controversy exists about the most effective and safest treatments for hyperthyroidism in children. This workshop will clarify some of the newer evidence based approaches to the diagnosis and management of hyperthyroidism, with a special emphasis on radioactive ablation.

  • Hyperthyroidism
    Scott A. Rivkees, Yale School of Medicine, New Haven, CT

3:45pm–5:15pm
2795A—Neonatal Diabetes
LWPES Workshop
Room 3001, Moscone West
Chair: Mark A. Sperling, Children's Hospital of Pittsburgh, Pittsburgh, PA

Target Audience: Endocrinologists and neonatologists.

Over the past few years much has been learned about the pathogenesis of neonatal diabetes. This workshop will impart knowledge on important considerations in the diagnosis and work-up of this rare condition.

4:00pm–7:30pm
Commercial Exhibits Open and Posters Available for Viewing
PAS Exhibits
Levels 1 and 2, Moscone West

Posters Available for Viewing: 4:00pm–7:30pm
Author Attendance: 5:15pm–7:15pm

Level 1:
– Developmental Biology
– Endocrinology
– Hematology–Oncology
– Neonatal Infectious Diseases
– Neonatology
– Nephrology

Level 2:
– Cardiology
– Developmental–Behavioral Pediatrics
– General Pediatrics
– Medical Education
– Neurology

5:15pm–6:00pm
2800—Clinical Pediatric Hypertension
PAS/ASPN/IPHA Poster Symposium
Room 2004, Moscone West
Chairs: Stephen R. Daniels and Deborah P. Jones

Sponsored jointly by the International Pediatric Hypertension Association and the American Society of Pediatric Nephrology

5:15pm–7:15pm
Poster Session I and PAS Opening Reception
PAS Poster Session
Levels 1 and 2, Moscone West

Posters Available for Viewing: 4:00pm–7:30pm
Author Attendance: 5:15pm–7:15pm

Level 1:
– Developmental Biology
– Endocrinology
– Hematology–Oncology
– Neonatal Infectious Diseases
– Neonatology
– Nephrology

Level 2:
– Cardiology
– Developmental–Behavioral Pediatrics
– General Pediatrics
– Medical Education
– Neurology

Includes:

  • SPR Student Research Award: Resuscitation of Non-Viable Infants: Will Neonatologists' Practice Change After the Born-Alive Infant Protection Act?
    Mya Sendowski, University of California, San Francisco, CA


Sunday, April 30

7:45am–9:00am
3080A—LWPES Business Meeting
LWPES Business Meeting
Room 3007-3011, Moscone West

8:00am–10:00am
3125—Developmental Origins of Adult Disease—Metabolism
PAS Platform Session
Room 3010-3012, Moscone West
Chairs: William W. Hay and Rebecca A. Simmons

9:00am–10:00am
3290A—LWPES Presidential Lecture
LWPES Presidential Plenary
Room 3007-3011, Moscone West
Chair: Alan D. Rogol, University of Virginia, Charlottesville, VA

Target Audience: Endocrinologists.

Judson J. Van Wyk Prize
Melvin M. Grumbach, 
Alan D. Rogol, University of Virginia, Charlottesville, VA

Pediatric Endocrinology Past and Present: Are We Ready for the Future?
Lynne L. Levitsky, Massachusetts General Hospital, Boston, MA

10:00am–11:45am
3325A—Endocrinology/Diabetes Awards
LWPES Platform Session
Room 3007-3011, Moscone West
Chairs: To be announced

LWPES Clinical Scholars Presentations

11:00am–4:00pm
Commercial Exhibits Open and Posters Available for Viewing
PAS Exhibits
Levels 1 and 2, Moscone West

Posters Available for Viewing: 11:00am–4:00pm
Author Attendance: 12:00pm–2:00pm

Level 1:
– Allergy, Immunology and Rheumatology
– Developmental-Behavioral Pediatrics
– Endocrinology
– Infectious Diseases
– General Pediatrics
– Hematology–Oncology

Level 2: 
– Cardiology
– Neonatal Neurology
– Neonatology

12:00pm–2:00pm
Poster Session II
PAS Poster Session
Levels 1 and 2, Moscone West

Posters Available for Viewing: 11:00am–4:00pm
Author Attendance: 12:00pm–2:00pm

Level 1:
– Allergy, Immunology and Rheumatology
– Developmental-Behavioral Pediatrics
– Endocrinology
– Infectious Diseases
– General Pediatrics
– Hematology–Oncology

Level 2: 
– Cardiology
– Neonatal Neurology
– Neonatology

Includes:

  • SPR Clinical Research Award: Accelerated Development in the Visual Areas of Preterm Infants? A Voxel-Based Morphometry Study on Diffusion Tensor MR Imaging (DTI)
    Maria Miranda, Copenhagen University Hospital, Hvidovre, Denmark

  • SPR Fellow's Basic Research Award: Myopalladin Mutations and Inherited Cardiomyopathies
    Enkhsaikhan Purevjav, Baylor College of Medicine, Houston, TX

  • SPR Fellow's Clinical Research Award: Novel Genotyping Technology To Classify Childhood Leukemia
    Joshua D. Schiffman, Stanford University, Palo Alto, CA

  • SPR House Officer Research Award: Erythropoietin Protein Expression in the Developing Human Eye
    Shrena Patel, University of New Mexico, Albuquerque, NM

2:00pm–4:00pm
3710—Non-Growth Related Issues in Girls with Turner Syndrome
PAS/LWPES Topic Symposium
Room 3003-3005, Moscone West
Chairs: Judith G. Hall, The University of British Columbia and BC Children's Hospital, Vancouver, BC, Canada; and Paul H. Saenger, Montefiore Medical Center, The Bronx, NY

Target Audience: Geneticists, endocrinologists, cardiologists and developmental pediatricians.

Although the focus of the pediatric endocrine community has been primarily on the growth issues of girls with Turner Syndrome, other non-growth issues continue to be described. This topic symposium will highlight these non-growth-related issues and illuminate the problems and strategies of dealing with them.

  • Evaluation of Congenital and Acquired Heart Disease in Turner Syndrome
    Carolyn A. Bondy, National Institute of Child Health and Human Development, Bethesda, MD

  • Skeletal Health
    Vladamir K. Bakalov, National Institute of Child Health and Human Development, Bethesda, MD

  • Non-verbal Learning Disabilities
    Marsha L. Davenport, University of North Carolina at Chapel Hill, Chapel Hill, NC

Sponsored jointly by the Lawson Wilkins Pediatric Endocrine Society and the Pediatric Academic Societies

2:00pm–5:00pm
3750—Endocrine Disrupters
PAS/LWPES Mini Course
Room 3010-3012, Moscone West
Chairs: Mary M. Lee, University of Massachusetts Medical School, Worcester, MA; and Henry Anhalt, Saint Barnabas Medical Center, Livingston, NJ

Target Audience: Endocrinologists, generalists, neonatologists and basic scientists.

Concerns regarding clinical consequences of endocrine disrupting chemicals have increased over the past decade as researchers have documented detrimental effects in wildlife. Federal attention to endocrine disrupters began in earnest in 1996 when the U.S. Congress passed the Food Quality Protection Act and amended the Safe Drinking Water Act. These laws mandated testing to determine if pesticides and industrial chemicals might behave like hormones; therefore, the U.S. EPA formed the Endocrine Disrupters Screening and Advisory Committee. In addition to direct effects, some environmental disrupters act through non-genomic actions, some of which persist for several generations. This program presenting innovative studies on mechanisms of action of endocrine disruptors will be of critical interest to endocrinologists, both clinical and basic scientists, as well as public health experts.

  • Prenatal Programming with Estrogen/Estrogen Mimetics
    Kenneth S. Korach, National Institute of Environmental Health Sciences, Research Triangle Park, NC

  • Epigenetic Transgenerational Actions of Endocrine Disruptors on Male Fertility and Other Diseases
    Michael K. Skinner, Washington State University, Pullman, WA

  • Prenatal Programming with Native and Environmental Steroids
    Vasantha Padmanabhan, University of Michigan, Ann Arbor, MI

Sponsored jointly by the Lawson Wilkins Pediatric Endocrine Society and the Pediatric Academic Societies

4:15pm–5:45pm
3805—Fetal Homeland Security: New Insights into Old Threats
PAS State of the Art Plenary
Room 3002-3008, Moscone West
Chairs: Phil W. Shaul, University of Texas Southwestern Medical Center, Dallas, TX; and Rashmin C. Savani, University of Texas Southwestern Medical Center, Dallas, TX

Target Audience: Neonatologists, pediatricians and researchers interested in perinatal biology.

In addition to premature birth, there are a select number of maternal conditions that have marked negative impact on the well being of the fetus and newborn. This symposium will highlight recent advances in our understanding of these classical threats to our most vulnerable pediatric patient population.

First, new knowledge of the mechanisms by which maternal diabetes alters embryonic and fetal development will be discussed. Second, the newly discovered role of circulating anti-angiogenic proteins of placental origin in the pathogenesis of preeclampsia will be presented. Finally, novel mechanisms by which biochemical events in the fetal lung trigger the initiation of labor will be discussed. Further advances in each of these realms will ultimately lead to new therapies to protect the fetus and yield healthy outcomes at term.

  • Mechanisms by Which Maternal Diabetes Modifies Embryonic and Fetal Development
    Kelle H. Moley, Washington University School of Medicine, St. Louis, MO

  • Role of Circulating Anti-angiogenic Proteins of Placental Origin in the Pathogenesis of Preeclampsia
    S. Ananth Karumanchi, Harvard Medical School, Beth Isreal Deaconess Medical Center, Boston, MA

  • Fetal–Maternal Signaling in the Initiation of Labor
    Carole R. Mendelson, University of Texas Southwestern Medical Center, Dallas, TX

4:15pm–5:45pm
3810—RNA Interference, Technological Development of siRNAs and Potential Treatments for Childhood Diseases
PAS State of the Art Plenary
Room 3016-3018, Moscone West
Chair: R. Alan B. Ezekowitz, Harvard Medical School, Massachusetts General Hospital, Boston, MA

Target Audience: Basic scientists studying a broad range of childhood diseases, translational scientists of all disciplines studying clinical implications of basic science research, clinical scientists studying childhood and other diseases in need of improved therapies and clinicians interested in cutting-edge science and its medical implications.

RNA interference is a recently discovered, naturally occurring intracellular process that regulates gene expression through the silencing of specific mRNAs. Methods of harnessing this natural pathway are being developed that allow the catalytic degradation of targeted mRNAs using specifically designed complementary small inhibitory RNAs (siRNA). siRNAs are being chemically modified to acquire drug-like properties. Numerous recent high-profile publications have provided proofs of concept that RNA interference may be useful therapeutically. Much of the design of these siRNAs can be accomplished bioinformatically, thus potentially expediting drug discovery and opening new avenues of therapy for many childhood diseases including uncommon pediatric and orphan diseases. A discussion of the science behind RNA interference will be followed by a presentation of the potential practical issues in applying this technology to disease. The program then describes two therapeutic programs currently under way with applications to pediatric diseases. A question-and-answer time will follow each discussion.

  • The Science of RNA Interference
    John J. Rossi, Beckman Research Institute of City of Hope, Duarte, CA

  • RNA Interference and Its Potential Applications for Controlling Disease
    Judy Lieberman, CBR Institute for Biomedical Research and Harvard Medical School, Boston, MA

  • Silencing the VEGF Pathway with siRNAs and the Potential Application to Retinopathy of Prematurity
    Pamela Pavco, Sirna Therapeutics, Boulder, CO

  • siRNA as Therapy for Respiratory Syncytial Virus
    John P. DeVincenzo, University of Tennessee School of Medicine, Memphis, TN

4:15pm–6:15pm
3845—Endocrinology: Insulin Resistance/Obesity
PAS/LWPES Poster Symposium
Room 3003-3005, Moscone West
Chairs: I. David Schwartz and Svetlana Ten

4:15pm–6:15pm
3850—Human Milk and Breastfeeding
PAS Poster Symposium
Room 3001, Moscone West
Chairs: Sheela R. Geraghty and Ardythe L. Morrow

7:00pm–9:00pm
Practical and Scientific Approaches to Growth Hormone: From Pediatrics to Adults
PAS Industry Sponsored Symposium
Golden Gate Hall A1-3, SF Marriott

Target Audience: Endocrinologists.